VYNE News and Press, VYNE Therapeutics Inc Com From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

VYNE Therapeutics Inc. (VYNE) is expected to report $-0.76 for Q3 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Th...

2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...

2023-11-03 10:02:39 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Cellectis, VYNE Therapeutics among healthcare movers

BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...

2023-10-30 13:43:38 ET Gainers: Miromatrix Medical MIRO +216% . Eargo ( EAR ) +52% . Kaixin Auto Holdings ( KXIN ) +49% . Reviva Pharmaceuticals Holdings ( RVPH ) +45% . Conduit Pharmaceuticals ( CDT ) +40% . Primech Holdings Ltd...

2023-10-30 12:16:36 ET DENVER, Colo., Oct. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VYNE Therapeutics Inc (NASDAQ: VYNE), Coherus BioSciences Inc (NASDAQ: CHRS), MeiraGTx Holdings PLC (N...

2023-10-30 07:46:55 ET More on VYNE Therapeutics Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE Therapeutics For further details see: Vyne Therapeutics jumps 52% on $8...

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritis Following completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 202...